FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $517,000 | -1.7% | 8,831 | -0.4% | 0.01% | +9.1% |
| Q3 2021 | $526,000 | -44.9% | 8,869 | -19.4% | 0.01% | -47.6% |
| Q2 2021 | $955,000 | -3.7% | 11,000 | -8.5% | 0.02% | -4.5% |
| Q1 2021 | $992,000 | -27.3% | 12,028 | -19.8% | 0.02% | -15.4% |
| Q4 2020 | $1,364,000 | +68.8% | 15,000 | -25.8% | 0.03% | +18.2% |
| Q3 2020 | $808,000 | +17.8% | 20,224 | +1.1% | 0.02% | +10.0% |
| Q2 2020 | $686,000 | +220.6% | 20,000 | +107.7% | 0.02% | +150.0% |
| Q1 2020 | $214,000 | +9.2% | 9,630 | -3.7% | 0.01% | +166.7% |
| Q4 2019 | $196,000 | -37.0% | 10,000 | -50.0% | 0.00% | -50.0% |
| Q3 2019 | $311,000 | -23.4% | 20,000 | 0.0% | 0.01% | -45.5% |
| Q2 2019 | $406,000 | -1.7% | 20,000 | -14.9% | 0.01% | +10.0% |
| Q1 2019 | $413,000 | +38.6% | 23,500 | +1.2% | 0.01% | -16.7% |
| Q4 2018 | $298,000 | -39.1% | 23,221 | -22.6% | 0.01% | -7.7% |
| Q3 2018 | $489,000 | – | 30,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |